首页>
外国专利>
Hitherto unknown composition for the treatment of essential thrombocythaemia
Hitherto unknown composition for the treatment of essential thrombocythaemia
展开▼
机译:迄今未知的用于治疗原发性血小板增多症的组合物
展开▼
页面导航
摘要
著录项
相似文献
摘要
The invention relates to novel formulations of anagrelide resulting in a non- immediate release of the active ingredient of anagrelide. The inventors have shown that pharmaceutical compositions comprising anagrelide particles, wherein at least 90% of said anagrelide particles are smaller than 10µm, in combination with lactose monohydrate provide a formulation with reduced release characteristics when administered to a patient. Optionally, the pharmaceutical composition can further comprise povidone, crospovidone, microcristalline cellulose and/or magnesium stearate.
展开▼